Among those PROTACs, SNIPER-2 (Table 3) efficiently degraded BCL-XL in malignant T-cell lymphoma cell line (MyLa 1929) while CRBN-based PROTACs that had high potency in other cancer cell lines showed compromised potency. Here, BCL2L1 is linked to cancer.